Tuulia Vallius1, Johanna Hynninen2, Jukka Kemppainen3, Victor Alves4, Kari Auranen5, Jaakko Matomäki6, Sinikka Oksa7, Johanna Virtanen8, Seija Grénman2, Annika Auranen9, Marko Seppänen3. 1. Department of Obstetrics and Gynecology, University of Turku and Turku University Hospital, PL 52, 20521, Turku, Finland. tuulia.vallius@utu.fi. 2. Department of Obstetrics and Gynecology, University of Turku and Turku University Hospital, PL 52, 20521, Turku, Finland. 3. Department of Clinical Physiology and Nuclear Medicine, Turku PET Centre, University of Turku and Turku University Hospital, Turku, Finland. 4. Department of Nuclear Medicine, Sao Joao Hospital Centre, Oporto, Portugal. 5. Center of Statistics and Department of Clinical Medicine, University of Turku, Turku, Finland. 6. Turku University Hospital, Clinical Research Centre, Turku, Finland. 7. Department of Obstetrics and Gynecology, Satakunta Central Hospital, Pori, Finland. 8. Medical Imaging centre of Southwest Finland, University of Turku and Turku University Hospital, Turku, Finland. 9. Department of Obstetrics and Gynecology, University of Tampere and Tampere University Hospital, Tampere, Finland.
Abstract
OBJECTIVE: To evaluate the predictive potential of total metabolic tumor volume (MTV) reduction during neoadjuvant chemotherapy (NACT) with 18F-FDG-PET/CT in an advanced FIGO stage III/IV epithelial ovarian cancer (EOC) patient cohort. METHODS: Twenty-nine primarily inoperable EOC patients underwent 18F-FDG-PET/CT before and after NACT. The pre- and post-NACT total MTV, in addition to the percentage MTV reduction during NACT, were compared with primary therapy outcome and progression-free survival (PFS). ROC-analysis determined an optimal threshold for MTV reduction identifying patients with progressive or stable disease (PD/SD) at the end of primary therapy. A multivariate analysis with residual tumor (0/>0), FIGO stage (III/IV) and MTV reduction compared to PFS was performed. The association between MTV reduction and overall survival (OS) was evaluated. RESULTS: The median pre- and post-NACT total MTV were 352 cm3 (range 150 to 1322 cm3) and 51 cm3 (range 0 to 417 cm3), respectively. The median MTV reduction during NACT was 89% (range 24% to 100%). Post-NACT MTV and MTV reduction associated with primary therapy outcome (MTV post-NACT p = 0.007, MTV reduction p = 0.001) and PFS (MTV post-NACT p = 0.005, MTV reduction p = 0.005). MTV reduction <85% identified the PD/SD patients (sensitivity 70%, specificity 78%, AUC 0.79). In a multivariate analysis, MTV reduction (p = 0.002) and FIGO stage (p = 0.003) were statistically significant variables associated with PFS. MTV reduction during NACT corresponded to OS (p = 0.05). CONCLUSION: 18F-FDG-PET/CT is helpful in NACT response evaluation. Patients with total MTV reduction <85% during NACT might be candidates for second-line chemotherapy and clinical trials, instead of interval debulking surgery.
OBJECTIVE: To evaluate the predictive potential of total metabolic tumor volume (MTV) reduction during neoadjuvant chemotherapy (NACT) with 18F-FDG-PET/CT in an advanced FIGO stage III/IV epithelial ovarian cancer (EOC) patient cohort. METHODS: Twenty-nine primarily inoperable EOC patients underwent 18F-FDG-PET/CT before and after NACT. The pre- and post-NACT total MTV, in addition to the percentage MTV reduction during NACT, were compared with primary therapy outcome and progression-free survival (PFS). ROC-analysis determined an optimal threshold for MTV reduction identifying patients with progressive or stable disease (PD/SD) at the end of primary therapy. A multivariate analysis with residual tumor (0/>0), FIGO stage (III/IV) and MTV reduction compared to PFS was performed. The association between MTV reduction and overall survival (OS) was evaluated. RESULTS: The median pre- and post-NACT total MTV were 352 cm3 (range 150 to 1322 cm3) and 51 cm3 (range 0 to 417 cm3), respectively. The median MTV reduction during NACT was 89% (range 24% to 100%). Post-NACT MTV and MTV reduction associated with primary therapy outcome (MTV post-NACT p = 0.007, MTV reduction p = 0.001) and PFS (MTV post-NACT p = 0.005, MTV reduction p = 0.005). MTV reduction <85% identified the PD/SDpatients (sensitivity 70%, specificity 78%, AUC 0.79). In a multivariate analysis, MTV reduction (p = 0.002) and FIGO stage (p = 0.003) were statistically significant variables associated with PFS. MTV reduction during NACT corresponded to OS (p = 0.05). CONCLUSION: 18F-FDG-PET/CT is helpful in NACT response evaluation. Patients with total MTV reduction <85% during NACT might be candidates for second-line chemotherapy and clinical trials, instead of interval debulking surgery.
Authors: Lalitha K Shankar; Annick Van den Abbeele; Jeff Yap; Robert Benjamin; Scott Scheutze; T J Fitzgerald Journal: Clin Cancer Res Date: 2009-03-10 Impact factor: 12.531
Authors: Anna Fagotti; Gabriella Ferrandina; Francesco Fanfani; Giorgia Garganese; Giuseppe Vizzielli; Vito Carone; Maria Giovanna Salerno; Giovanni Scambia Journal: Am J Obstet Gynecol Date: 2008-09-17 Impact factor: 8.661
Authors: Johanna Hynninen; Annika Auranen; Olli Carpén; Kirsti Dean; Marko Seppänen; Jukka Kemppainen; Maija Lavonius; Irina Lisinen; Johanna Virtanen; Seija Grénman Journal: Gynecol Oncol Date: 2012-04-24 Impact factor: 5.482
Authors: M Petrillo; G Vizzielli; F Fanfani; V Gallotta; F Cosentino; V Chiantera; F Legge; V Carbone; G Scambia; A Fagotti Journal: Gynecol Oncol Date: 2015-07-18 Impact factor: 5.482
Authors: Johannes B Roedl; Rivka R Colen; Nagaraj S Holalkere; Alan J Fischman; Noah C Choi; Michael A Blake Journal: Radiother Oncol Date: 2008-08-11 Impact factor: 6.280
Authors: Andrew McPherson; Andrew Roth; Emma Laks; Tehmina Masud; Ali Bashashati; Allen W Zhang; Gavin Ha; Justina Biele; Damian Yap; Adrian Wan; Leah M Prentice; Jaswinder Khattra; Maia A Smith; Cydney B Nielsen; Sarah C Mullaly; Steve Kalloger; Anthony Karnezis; Karey Shumansky; Celia Siu; Jamie Rosner; Hector Li Chan; Julie Ho; Nataliya Melnyk; Janine Senz; Winnie Yang; Richard Moore; Andrew J Mungall; Marco A Marra; Alexandre Bouchard-Côté; C Blake Gilks; David G Huntsman; Jessica N McAlpine; Samuel Aparicio; Sohrab P Shah Journal: Nat Genet Date: 2016-05-16 Impact factor: 38.330
Authors: N George Mikhaeel; Daniel Smith; Joel T Dunn; Michael Phillips; Henrik Møller; Paul A Fields; David Wrench; Sally F Barrington Journal: Eur J Nucl Med Mol Imaging Date: 2016-02-23 Impact factor: 9.236
Authors: Jan Philipp Ramspott; Thaïs Baert; Michelle Louise MacKintosh; Alexander Traut; Beyhan Ataseven; Mareike Bommert; Florian Heitz; Helmut Plett; Stephanie Schneider; Kai-Uwe Waltering; Sebastian Heikaus; Philipp Harter; Andreas du Bois Journal: Arch Gynecol Obstet Date: 2021-03-04 Impact factor: 2.344
Authors: Roberto C Delgado Bolton; Nicolas Aide; Patrick M Colletti; Annamaria Ferrero; Diana Paez; Andrea Skanjeti; Francesco Giammarile Journal: Eur J Nucl Med Mol Imaging Date: 2021-07-03 Impact factor: 9.236